glp 1 agonist herbal Resmetirom and GLP-1 agonists for MASH: complementary rather than exclusive Swissmedic issues warning against falsified

Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic -cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection

10.4049/jimmunol.1302338 J

In vitro, Apt-1 disrupted the maintenance (but not initiation) of the myCAF phenotype and reduced cancer stemness markers (Sox2, Oct4, Nanog), leading to a significant decrease in tumorsphere formation

While multiple trials have shown significant cardiovascular benefits, the evidence reveals varying magnitudes of effect and some neutral results, indicating that cardiovascular protection may not be universally consistent across all GLP-1 RAs (Table 6) [81]